NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital co-leads a $165 million oversubscribed Series A financing in Bionyra Pharma to advance Clinical-Stage Pipeline of next generation biologics for Immune-Mediated Inflammatory Diseases
The financing aims to accelerate the development of near-clinical and clinical drug candidates offering targeted treatments designed to maximize efficacy in severe inflammatory diseases (including atopic dermatitis and inflammatory bowel disease (IBD)), where...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders
Proceeds will support two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick...
Jeito Capital Strengthens Leadership for Next Chapter of Growth:Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
Paris, May 12 2024 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund...
Jeito Capital co-leads the oversubscribed €78 million financing in Augustine Therapeutics to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases
Proceeds from the financing will advance Augustine’s lead candidate, AGT-100216, through a Phase 2...
Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients
Callio Therapeutics is a biotechnology company developing multi-payload ADCs with technology and...
Jeito Capital leads $67.5 million (€64.4 million) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease
Proceeds of financing will support two double-blinded Phase 2 trials for its lead candidate XC001,...
Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials
Investment will support the ongoing Phase 2b/3 and planned pivotal Phase 3 clinical trial for...
Face to face
Meet Jeito
12-15
January
All day long
JPM Healthcare Conference 2026
Jeito will be present at the 44th JPM Healthcare Conference 2026, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.